Related references
Note: Only part of the references are listed.Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination
Eleonore De Guillebon et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Qingyang Xiao et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Sohyun Hwang et al.
SCIENTIFIC REPORTS (2020)
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Jeffrey M. Conroy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
Alessandro Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Circulating PD-L1-exosomes to monitor tumor response in melanoma patients.
Charlee Nardin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG 50800 neoadjuvant trial
Xiaotong Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
P. Hofman et al.
ANNALS OF ONCOLOGY (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Laurent Mhanna et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Venkatesh Sivanandam et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
Vera Kloten et al.
CELLS (2019)
Deglycosylated PD-L1 might be a better biomarker
Peter Sidaway
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Mutation-Derived Neoantigens for Cancer Immunotherapy
John C. Castle et al.
FRONTIERS IN IMMUNOLOGY (2019)
DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
Gang Xue et al.
FRONTIERS IN GENETICS (2019)
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
Jian Wang et al.
SCIENTIFIC REPORTS (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma
Jason A. Carter et al.
NATURE MEDICINE (2019)
Reply to: 'IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma'
Noam Auslander et al.
NATURE MEDICINE (2019)
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Sabrina A. Hogan et al.
CANCER IMMUNOLOGY RESEARCH (2019)
The prognostic value of immunoscore in patients with colorectal cancer: A systematic review and meta-analysis
Guorui Sun et al.
CANCER MEDICINE (2019)
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
Emeric Limagne et al.
ONCOIMMUNOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
Reinhard Buettner et al.
ESMO OPEN (2019)
The Discovery of Biomarkers in Cancer Immunotherapy
Anil P. George et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
Christiane Kuempers et al.
FRONTIERS IN MEDICINE (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
Ann Rita Halvorsen et al.
ACTA ONCOLOGICA (2018)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
B cells as biomarkers: predicting immune checkpoint therapy adverse events
Shannon M. Liudahl et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
Matteo Allegretti et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Enrico Munari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A potential biomarker for anti-PD-1 immunotherapy
Sangeeta Goswami et al.
NATURE MEDICINE (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Ludmila Danilova et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
Mariana Aris et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond
Kristina Buder-Bakhaya et al.
FRONTIERS IN IMMUNOLOGY (2018)
Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
Etienne Giroux Leprieur et al.
ONCOIMMUNOLOGY (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Neus Martinez-Bosch et al.
CANCERS (2018)
Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs
Frederick S. Varn et al.
CANCER RESEARCH (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander et al.
NATURE MEDICINE (2018)
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Xian Shen et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Trends in the global immuno-oncology landscape
Jun Tang et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
Lisa H. Butterfield et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Approach to evaluating tumor mutational burden in routine clinical practice
John Truesdell et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
Alessandra Cesano et al.
BIOMEDICINES (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians
Michael Allgaeuer et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Nicola Normanno et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
Alvaro Moreira et al.
IMMUNOTHERAPY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn et al.
MOLECULAR IMMUNOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Chan-Young Ock et al.
NATURE COMMUNICATIONS (2017)
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Yuko Oya et al.
ONCOTARGET (2017)
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Alexandra Snyder et al.
PLOS MEDICINE (2017)
Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Sebastian Marwitz et al.
CLINICAL EPIGENETICS (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy
Yulian Khagi et al.
CLINICAL CANCER RESEARCH (2017)
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Lillian L. Siu et al.
CLINICAL CANCER RESEARCH (2017)
γδ T Cells: Unexpected Regulators of Cancer Development and Progression
Christopher Fleming et al.
TRENDS IN CANCER (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Monitoring immune responses in the tumor microenvironment
Jennifer A. Wargo et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Andrew Js Furness et al.
IMMUNOTHERAPY (2016)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer
Kazuhiko Shien et al.
LUNG CANCER (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma
Xiang Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Sander Kelderman et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
Cancer classification using the Immunoscore: a worldwide task force
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Quality Assessment and Correlation of Microsatellite Instability and Immunohistochemical Markers among Population- and Clinic-Based Colorectal Tumors Results from the Colon Cancer Family Registry
Mine S. Cicek et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Tumor-infiltrating γδ T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway
Guangyong Peng et al.
IMMUNITY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Share Paper
